The tweet was deleted by the author.
But we saved everything 🙂.
Editas Medicine unveiled new preclinical data for its investigational therapy EDIT-401, focusing on durability in treating hyperlipidemia, at AHA2026.
The findings suggest that EDIT-401 could emerge as a transformative option, supporting its continued development for patients with hyperlipidemia.
View post on X Loading...
Editas Medicine previously announced plans to unveil preclinical data on EDIT-401 at an American Heart Association event. The company has also participated in the ESGCT 33rd Annual Congress with poster presentations and an investor conference appearance. These activities reflect ongoing efforts to advance its research pipeline.